Publications by authors named "D Teschner"
Article Synopsis
- * Findings indicated that patients' median age at first ASCT has increased, while the use of tandem ASCT decreased, and there were improved survival rates across all age groups, especially older patients.
- * Careful patient selection is crucial for tandem ASCT, as it is less beneficial for those with certain conditions (ISS III and renal impairment), older patients, and those who achieve complete response after initial ASCT.
Introduction: Men are generally more susceptible to bacterial infections than women. Central venous catheters (CVCs), often used to administer systemic treatment in patients with cancer, are an important source of infection. However, little is known about sex-specific differences of CVC-related bloodstream infections (CRBSIs) in patients with cancer.
View Article and Find Full Text PDFAllogeneic hematopoietic stem cell transplantation (allo-HSCT) is the best curative treatment modality for many malignant hematologic disorders. In the absence of a matched related donor, matched unrelated donors (MUDs) and haploidentical donors are the most important stem cell sources. In this registry-based retrospective study, we compared the outcomes of allo-HSCTs from 10/10 MUDs with antithymocyte globulin (ATG)-based regimens (n = 7050) vs haploidentical transplants (Haplo-Tx) using posttransplant cyclophosphamide (PT-CY Haplo; n = 487) in adult patients with hematologic malignancies between 2010 and 2020.
View Article and Find Full Text PDFArticle Synopsis
- The oxygen evolution reaction (OER) is crucial for generating green hydrogen and other renewable energy sources, with iridium oxohydroxides (IOHs) being effective catalysts due to their balance of activity and stability in acidic conditions.
- While amorphous IOHs are highly active, they lack stability, whereas crystalline IOHs are more stable but typically less active.
- This research identifies crystalline IrOOH nanosheets as a promising catalyst, offering high activity and stability, and establishes simple design rules based on atomic-level relationships to guide future development of efficient OER catalysts.
Current consensus recommends hematopoietic cell transplantation (HCT) for patients with myelofibrosis with intermediate or high-risk disease and age of less than 70 years. However, a higher chronological age should not be prohibitive for the eligibility decision in general, acknowledging that current life expectancy for the general population aged 70 years is ∼15 years, and current numbers of patients transplanted at 70 years or older is steadily increasing. The following study aimed to evaluate characteristics and outcomes of HCT in 115 myelofibrosis patients aged 70 years or older.
View Article and Find Full Text PDF